PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues

Abstract excerpt

mutations. Differences in clinical trial design have contributed to distinct indications for each of the PARP inhibitors. Toxicity patterns are also emerging that suggest agents differ in their normal tissue tolerance - beyond what might be expected by dose variations and/or exposure to prior treatment. PARP inhibitor resistance is an increasingly relevant issue as the drugs move to the forefront of advanced...

Topics

Join the communities discussing this publication.

• Integrated Circuits and Semiconductor Failure Analysis
• Ovarian cancer diagnosis and treatment
• PARP inhibition in cancer therapy